A non‑hormonal male birth control pill, YCT‑529, has completed its first Phase 1a human trial, showing no serious side effects and strong tolerance among participants, reported India Today. The drug, developed by YourChoice Therapeutics with input from the University of Minnesota and Columbia University, works by blocking retinoic acid receptor α in the testes to temporarily halt sperm production – without affecting hormone levels or libido.
Promising Results From Phase 1
The early trial involved 16 healthy vasectomised men aged 32–59, each given single ascending doses ranging from 10 mg to 180 mg, with a subset tested under fed and fasted conditions. Blood samples confirmed that the drug reached adequate levels and cleared from the system promptly. No adverse changes were detected in heart rate, hormones, inflammatory markers, sexual function, or mood.
The Science Behind YCT‑529
YCT‑529 acts as a retinoic acid receptor‑α (RAR‑α) antagonist, disrupting vitamin A‑mediated gene activity essential for sperm formation. Preclinical studies showed it is 99 percent effective in preventing pregnancy in male mice and significantly reduced sperm counts in primates. Importantly, fertility returned within weeks after discontinuation, and no adverse effects were observed.
Why This Could Be Game‑Changing
Until now, the only male contraceptive choices – condoms and vasectomy – have been limited or irreversible. YCT‑529 offers the first reversible, non‑hormonal, daily pill option for men. Participants tolerated it well, whether taken with or without food, and researchers view it as a significant milestone on the path toward more equitable family planning and men’s reproductive autonomy.
Next Steps: Phase 2 & Beyond
Follow‑up trials are already underway. The second human study involves 28‑ and 90‑day dosing regimens to evaluate long‑term safety, pharmacokinetics and sperm‑reducing efficacy. If Phase 2 confirms these findings, larger trials will be needed before seeking regulatory approvals.
Growing Male Contraception LandscapeYCT‑529 is joining a new wave of non‑hormonal male contraceptive research, alongside alternatives like Dimethandrolone undecanoate (DMAU) and RISUG, which offer either hormonal or barrier methods. However, YCT‑529 stands out due to its oral delivery and reversible, side‑effect‑free profile.
Photo Credit: India Today
For more health related stories click here
Follow us for latest updates:
